Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed

AIDS

Volumn 12, Issue 11, 1998, Pages 1333-1340

  Bellman, Paul C ^a,b  

^a LENOX HILL HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

Combination chemotherapy; HIV 1; Reverse transcriptase inhibitor

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DELAVIRDINE; INDINAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; BISEXUALITY; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW BACK PAIN; LYMPHOCYTE COUNT; MALE; MULTICENTER STUDY; NAUSEA; NEPHROLITHIASIS; PRIORITY JOURNAL; PROTEINURIA; RASH; TREATMENT FAILURE; VIRUS LOAD;

EID: 0032581593     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199811000-00015     Document Type: Article

References (17)

1. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
2. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
3. Kuritzkes DR, Quinn JB, Benoit SL, et al.: Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996, 10:975-981.
4. Althaus IL, Chou JJ, Gonzales AJ, et al.: Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E. Biochem Pharmacol 1994, 47:2017-2028.
5. Sargent S, Green S, Para M, et al.: Sustained plasma viral burden reductions and CD4 increases in HIV-1 infected patients with Rescriptor (DLV) + Retrovir (ZDV) + Epivir (3TC). Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 699].
6. Cox SR, Ferry JJ, Batts DH, et al.: Delavirdine (D) and marketed protease inhibitors (Pls): pharmacokinetic (PK) interaction studies in healthy volunteers. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, January 1997 [abstract 372].
7. Eron JJ, Benoit SL, Jemsek J, et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic milliliter. N Engl J Med 1995, 333:1662-1669.
8. Wathen LK, Freimuth WW, Cox SR, et al.: Phenotypic changes in viral isolates treated with Rescriptor tablets (DLV) plus zidovudine (ZDV) or zidovudine alone. International Workshop on HIV Resistance, Treatment Strategies and Eradication. St Petersburg, June 1997 [abstract 41].
9. Wein LM, Zenios SA, Nowak MA: Dynamic multidrug therapies for HIV: A control theoretic approach. J Theor Biol 1997, 185:15-29.
10. Ruiz L, Nijhuis M, Boucher CAB, et al.: Phenotypic and genotypic resistance to indinavir in individuals with advanced HIV-1 disease. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St Petersburg, June 1997 [abstract 37].
11. Merry C, Barry MG, Mulcahy F, et al.: Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997, 11:F29-F33.
12. Schapiro JM, Winters MA, Stewart F, et al.: The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996, 124:1039-1050.
13. Korneyeva M, Molla A, Kempf D, et al.: Clinical and virological responses to ritonavir, an inhibitor of HIV protease. Eleventh International Conference on AIDS. Vancouver, July 1996 [abstract Mo.B.1137].
14. Hicks CB, Lehman L, Eron J, et al.: Safety and efficacy of ritonavir administered at two potentially maximum tolerated doses. Eleventh International Conference on AIDS. Vancouver, July 1996 [abstract Mo.B. 415].
15. Powderly W, Sension M, Conant A, et al.: The efficacy of Viracept (nelfinavir mesylate, NFV) in pivotal Phase II/III double-blind randomized controlled trials as monotherapy and in combination with d4T or AZT/3TC. 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 370].
16. Mascolini M, Nelfinavir is number 4 - but should it bat cleanup, or lead off? J Int Assoc Phy AIDS Care 1997, June: 17-21.
17. Carpenter CCJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA Panel. JAMA 1997, 227:1962-1969.